Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
AMGN has lost nearly 5% this week and 8% over the past month, closing at $402.60, and the most interesting tension right now is that short sellers are quietly retreating while the analyst community grows more cautious.
The borrow market tells a clean story: shorts are not pressing this name. Short interest has eased to 2.2% of the free float, down about 2% over the past week and the lowest level in the 30-day window. Borrowing costs have collapsed to 0.22%, roughly half what they were a month ago, and availability is extremely loose at over 8,000%, meaning there are far more shares available to lend than are currently borrowed. That is not the setup of a name bears are crowding into. Options positioning supports the same read. The put/call ratio has dropped to 1.04, nearly 1.5 standard deviations below its 20-day average of 1.13 and well off the 52-week high of 1.38, suggesting protection-buying has eased materially over recent weeks. Together, the lending and options picture points to a market that is less nervous about Amgen than it was through most of September, even as the stock has continued to slide.
The Street is more divided. Two moves landed on Wednesday. Morgan Stanley trimmed its target to $359 from $362 while keeping an Equal-Weight rating, a marginal reduction but from a bellwether firm that sits below the current price. Truist Securities moved in the opposite direction, lifting its Hold target to $380 from $362, still a discount to where the stock trades. That mild divergence reflects a broader pattern in recent weeks: HSBC downgraded to Hold in early September, BMO Capital cut to Market Perform around the same time, and Scotiabank went the other way with a $500 Sector Outperform target. The mean price target now sits at $391, a modest discount to the $402.60 close, which itself is a fairly unusual setup for a large-cap biotech and suggests the consensus has drifted below market price rather than leading it. Factor scores are broadly neutral: EPS momentum ranks in the 47th to 62nd percentile range depending on the horizon, EPS surprise ranks in the 33rd percentile, and the dividend score stands out at the 99th percentile, a reminder that income investors remain a structural buyer.
The bull and bear cases are well-defined. Bulls point to Amgen's six key growth drivers running 26% higher year on year in Q2 2026, with Repatha and Tezspire posting prescription growth of roughly 32% and 49% respectively through July. Pipeline optionality, including dazodalibep's expected Phase III completion in the second half of 2026 and readouts across Uplizna and MariTide, adds further upside argument. Bears anchor on clinical and regulatory risk, pointing specifically to the Novartis pelacarsen failure as evidence that cardiovascular science in the Lp(a) space can disappoint even late in development. For Amgen, which has its own Lp(a)-adjacent exposure, that outcome raised questions about how reliable its pipeline conversion will be in offsetting lifecycle risk across the established portfolio.
Medicaid data from the Centers for Medicare & Medicaid Services adds a wrinkle on the demand side. Medicaid units reimbursed for Amgen products fell 24% against Q1 last year, and Medicaid prescriptions were down 23% over the same period. These are publicly reported figures for Q1 2026 and carry no lead relationship to Amgen's reported financials in ORTEX's dataset, so they cannot be read as a signal for the upcoming print. But they describe a meaningful volume decline within the government-payer channel that bears watching against the commercial momentum the bull case emphasises.
Separately, retail attention has picked up. Wikipedia traffic for Amgen ran at a z-score of 2.83 relative to its own 90-day history as of mid-September, a high reading by the stock's own standards, though attention is a branding signal rather than a revenue indicator.
The next earnings date is 5 November. With the stock below most analyst targets, short sellers retreating and options turning less defensive, the setup into that print is less about positioning extremes and more about whether the commercial momentum story can hold against a softening Medicaid channel and fresh clinical-trial uncertainty in the Lp(a) space.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
